Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
- Tuesday, December 3, 2019, 7:40
- Business
- Add a comment
FREMONT, Calif., Dec. 3, 2019 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive topline results from PHREEDOM, a long-term…
About the Author
adminasapcorp has written 39125 stories on this site.